methionine has been researched along with gemcitabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bouvet, M; Han, Q; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, S; Lwin, TM; Miyake, K; Miyake, M; Oshiro, H; Tan, Y; Unno, M | 1 |
1 review(s) available for methionine and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for methionine and gemcitabine
| Article | Year |
|---|---|
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Injections, Intraperitoneal; Male; Methionine; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Recombinant Proteins; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |